Hormone therapy in elderly breast cancer patients with comorbidities

Critical Reviews in Oncology/Hematology

Volumn 73, Issue 1, 2010, Pages 92-98

  Crivellari, Diana ^a   Spazzapan, Simon ^a   Puglisi, Fabio ^b   Fratino, Lucia ^a   Scalone, Simona ^a   Veronesi, Andrea ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Adjuvant; Elderly breast cancer; Hormonal therapy; Metastasis; Toxicity

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2D6; ESTROGEN RECEPTOR; EXEMESTANE; FULVESTRANT; LETROZOLE; NEUROLEPTIC AGENT; PLACEBO; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; ZOLEDRONIC ACID;

AGED; ARTHRALGIA; ARTICLE; BONE METASTASIS; BRAIN ISCHEMIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CARDIOVASCULAR DISEASE; CATARACT; CEREBROVASCULAR ACCIDENT; COMORBIDITY; DEEP VEIN THROMBOSIS; DISEASE FREE SURVIVAL; DRUG BLOOD LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; EVENT FREE SURVIVAL; FRACTURE; GERIATRIC ASSESSMENT; GERIATRIC PATIENT; HEART INFARCTION; HOT FLUSH; HUMAN; LIFE EXPECTANCY; LUNG EMBOLISM; METRONOMIC DRUG ADMINISTRATION; MYALGIA; OSTEOLYSIS; OSTEOPOROSIS; OVERALL SURVIVAL; PATIENT COMPLIANCE; POSTMENOPAUSE; RISK REDUCTION; SIDE EFFECT; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VAGINA BLEEDING; VAGINA DISCHARGE;

EID: 83055187150     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.02.003     Document Type: Review

References (61)

1. Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute Bethesda MD http://seer.cancer.gov/csr/1975_2005/.
2. Franceschi S, La Vecchia C. Cancer epidemiology in the elderly. Crit Rev Oncol Hematol 2001;39:219-26.
3. IARC. Cancer incidence in five continents, vol. VIII. Lyon: IARC; 2002.
4. Chu KC, AndersonWF. Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. Breast Cancer Res Treat 2002;74:199-211.
5. Diab SG, Elledge RM, Clark GM. Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 2000;92:550-6.
6. Daidone MG, Coradini D, Martelli G, et al. Primary breast cancer in elderly women: biological profile and relation with clinical outcome. Crit Rev Oncol Hematol 2003;45:313-25.
7. Molino A, Giovannini M, Auriemma A, et al. Pathological, biological and clinical characteristics, and surgical management of elderlywomen with breast cancer. Crit Rev Oncol Hematol 2006;59:226-33.
8. Durbecq V, Ameye L, Veys I, et al. A significant proportion of elderly patients develop hormone-dependant "luminal B" tumours associated with aggressive characteristics. Crit Rev Oncol Hematol 2008;67(1):80-92.
9. Yancik R, ErshlerW, SatarianoW, et al. Report of the National Institute on Aging Task Force on Comorbidity. J Gerontol A 2007;62:275-80.
10. Extermann M, Balducci L, Lyman GH. What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 2000;18:1709-17.
11. Yancik R, Wesley MN, RiesLAG, et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 2001;285:885-92.
12. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007;25:1824-31.
13. Monfardini S, Ferrucci L, Fratino L, et al. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer 1996;77:395-401.
14. Biganzoli L, Goldhirsch A, Straehle C, et al. Adjuvant chemotherapy in elderly patients with breast cancer: a survey of the Breast International Group (BIG). Ann Oncol 2004;15(2):207-10.
15. Repetto L, Fratino L, Audisio R, et al. Comprehensive geriatric assessment adds information to eastern cooperative oncology group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol 2002;20:494-502.
16. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83.
17. Parmalee PA, Thuras PD, Katz IR, Lawton MP. Validation of the Cumulative Illness Rating Scale in a geriatric residential population. J Am Geriatr Soc 1995;43:130-7.
18. SatarianoWA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-10.
19. Louwman WJ, Janssen-Heijnen MLG, Houterman S, et al. Less extensive treatment and inferior prognosis for breast cancer patient with comorbidity: a population-based study. Eur J Cancer 2005;41:779-85.
20. Hurria A, Leung D, Trainor K, et al. Factors influencing treatment patterns of breast cancer patients age 75 and older. Crit Rev Oncol/Hematol 2003;46:121-8.
21. Gennari R, Curigliano G, Rotmensz N, et al. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients. Cancer 2004;101(6):1302-10.
22. Goetz MP, Kamal A, Ames MM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 2008;83(1):160-6.
23. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overviewof the randomised trials. Lancet 2005;365:1687-717.
24. Crivellari D, Price K, Gelber RD, et al. Adjuvant endocrine therapy compared with no systemic therapy for elderlywomen with early breast cancer. 21-year results of International Breast Cancer Study Group Trial IV. J Clin Oncol 2003;21:4517-23.
25. Wiseman H, Pagana G, Rice-Evans C, et al. Protective actions of tamoxifen and 4-hydroxytamoxifen against oxidative damage to human low-density lipoproteins: a mechanism accounting for the cardioprotective action of tamoxifen? Biochem J 1993;292:635-8.
26. Rutqvist LE, Mattsson A. Cardiac and thromboembolic morbidity and postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993;85:1398-406.
27. Liu CL, Yang TL. Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. Breast Cancer Res Treat 2003;79:11-6.
28. Reis SE, Costantino JP, Wickerham L, et al. Cardiovascular effects of tamoxifen in women with and without heart disease: Breast Cancer Prevention Trial. J Natl Cancer Inst 2001;93:16-21.
29. Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Ger Intern Med 2003;18:937-47.
30. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. New Engl J Med 2006;355:125-37.
31. Dunn BK, Ford LG. From adjuvant therapy to breast cancer prevention: BCPT and STAR. Breast J 2001;7(3):144-57.
32. ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9.
33. ATAC Trialists Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2.
34. Forbes JF, Cuzick J, Buzdar A, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9(1):45-53.
35. The Breast International Group BIG 1-98. Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. N Engl J Med 2005;353:2747-57.
36. Mouridsen HT, Giobbie-Hurder A, Mauriac L, et al. BIG 1-98: a randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Abstract 13, The 31st Annual SABCS December 10-14, 2008.
37. Mouridsen HT, Kashaviah A, Coates AS, et al. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG1-98 trial. J Clin Oncol 2007;25:5715-22.
38. Crivellari D, Zhuoxin S, Coates AS, et al. Letrozole compared with tamoxifen for elderly patients with endocrine responsive early breast cancer: The BIG 1-98 Trial. J Clin Oncol 2008;26:1972-9.
39. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment on the use of Aromatase Inhibitors as adjuvant therapy for postmenopausalwomen with hormone receptorpositive breast cancer: Status Report 2004. J Clin Oncol 2005; 3:1-11.
40. Coombes RC, Hall E, Gibson LJ, et al. A randomised trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:1081-92.
41. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole (ITA) trial. J Clin Oncol 2005;23:5138-47.
42. Jakesz R, JonatW, Gnant M, et al. Switching of postmenopausalwomen with endocrine-responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-62.
43. Ingle JN, Dowsett M, Cuzick J, et al. Aromatase inhibitors versus tamoxifen as adjuvant therapy for postmenopausal women with estrogen receptor positive breast cancer: meta-analyses of randomized trials of monotherapy and switching strategies. Abstract 12, The 31st Annual SABCS December 10-14, 2008.
44. Goss P, Ingle J, Pater JL, et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008;26(12):1948-55.
45. Muss HB, Tu D, Ingle JN, et al. Efficacy, toxicity and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG Intergroup trialMA17. J Clin Oncol 2008;26(12):1956-64.
46. Chapman JA, Meng D, Shepherd L, et al. Competing causes of death from a randomised trial of extended adjuvant endocrine therapy for breast cancer. J Natl Cancer Inst 2008;100(4):252-60.
47. Kanis JA, Johnell O, De Laet C, et al. International variation in hip fracture probabilities: implications for risk assessment. J Bone Miner Res 2002;17:1237-44.
48. Braithwaite RS, Col NF, Wong JB. Estimating hip fracture morbidity, mortality and costs. J Am Geriatr Soc 2003;51:364-70.
49. Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008;19:1407-16.
50. BrufskyA, HarkerWG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausalwomen with early breast cancer. J Clin Oncol 2007;25:829-36.
51. Eidtmann H, Bundred NJ, DeBoer R, et al. The effect of zoledronic acid on aromatase inhibitor associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36 months followup of ZO-FAST. Abstract 44, The 31st Annual SABCS December 10-14, 2008.
52. Jenkins V, Atkins L, Fallowfield L. Does endocrine therapy for the treatment and prevention of breast cancer affect memory and cognition? Eur J Cancer 2008;43:1342-7.
53. Jenkins V, Shilling V, Fallowfield L, et al. Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psychooncology 2004;13:61-6.
54. Minisini AM, De Faccio S, Ermacora P, et al. Cognitive functions and elderly cancer patients receiving anticancer treatment: a prospective study. Crit Rev Oncol Hematol 2008;67:71-9.
55. Owusu C, Buist DSM, Field TS, et al. Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 2008;26:549-55.
56. Biganzoli L, Licitra S, Claudino W, et al. Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients-a jungle? Eur J Cancer 2007;43:2270-8.
57. Howell A, Robertson JFR, Quaresma AJ, et al. Fulvestrant, formerly ICI: 182780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396-403.
58. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386-95.
59. Bottini A, Generali D, Brizzi MP, et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. J Clin Oncol 2006;24:3623-8.
60. Woo SB, HellsteinJW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaw. Ann Intern Med 2006;144:753-61.
61. Botteman M, Barghout V, Stephens J, et al. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol 2006;17:1072-82